文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

术前诊断为原位导管癌的乳腺,即使表现为小肿块,术后标本中出现浸润性癌灶的风险也很高。

Preoperatively diagnosed ductal cancers in situ of the breast presenting as even small masses are of high risk for the invasive cancer foci in postoperative specimen.

作者信息

Szynglarewicz Bartlomiej, Kasprzak Piotr, Halon Agnieszka, Matkowski Rafal

机构信息

Department of Surgical Oncology, Lower Silesian Oncology Centre, Plac Hirszfelda 12, 53-413, Wroclaw, Poland.

Department of Breast Imaging, Lower Silesian Oncology Centre, Wroclaw, Poland.

出版信息

World J Surg Oncol. 2015 Jul 16;13:218. doi: 10.1186/s12957-015-0641-3.


DOI:10.1186/s12957-015-0641-3
PMID:26179898
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4504096/
Abstract

BACKGROUND: In ductal carcinoma in situ of the breast (DCIS), histologic diagnosis obtained before the definitive treatment is related to the risk of underestimation if the presence of invasive cancer is found postoperatively. These patients need a second operation to assess the nodal status. We evaluated the upstaging rate in patients with mass-forming DCIS. METHODS: Sixty-three women with pure DCIS presenting as sonographic mass lesion underwent vacuum-assisted or core-needle biopsy and subsequent surgery. Rates of postoperative upstaging to invasive cancer were calculated and compared with clinical character and size of DCIS. RESULTS: Median age of patients (range) was 63 years (27-88) while median diameter of DCIS was 11 mm (6-60). Fifty-six percent of DCIS were upstaged. Patient age did not differ significantly between groups with and without final invasion (median, mean, SD): 63, 61.4, 12.5 vs 62, 61.2, 10.6 years, respectively (P=0.659). The difference of DCIS size between these groups was statistically important (median, mean, SD): 13, 17.3, 11.4 vs 9.5, 9.8, 3.2 mm, respectively (P=0.0003). Mass size and palpability were significant risk factors (P<0.001 and P<0.01, respectively). Rate of underestimation for mass with diameter≤10 mm, 10-20 mm and >20 mm was 37, 64 and 91%, respectively. CONCLUSIONS: DCIS diagnosed on minimal-invasive biopsy of even small sonographic mass is of high risk for the upstaging to invasive cancer after final surgical excision. In these patients, subsequent intervention is needed for nodal status assessment. They are good candidates for the sentinel node biopsy during the breast operation to avoid multi-step surgery.

摘要

背景:在乳腺导管原位癌(DCIS)中,在 definitive 治疗前获得的组织学诊断与术后发现浸润性癌时低估风险相关。这些患者需要二次手术来评估淋巴结状态。我们评估了形成肿块型 DCIS 患者的分期上调率。 方法:63 例表现为超声肿块病变的纯 DCIS 女性患者接受了真空辅助或粗针活检及随后的手术。计算术后上调至浸润性癌的发生率,并与 DCIS 的临床特征和大小进行比较。 结果:患者的中位年龄(范围)为 63 岁(27 - 88 岁),而 DCIS 的中位直径为 11 毫米(6 - 60 毫米)。56%的 DCIS 出现分期上调。有最终浸润和无最终浸润组的患者年龄无显著差异(中位数、均值、标准差):分别为 63、61.4、12.5 岁和 62、61.2、10.6 岁(P = 0.659)。这些组之间 DCIS 大小的差异具有统计学意义(中位数、均值、标准差):分别为 13、17.3、11.4 毫米和 9.5、9.8、3.2 毫米(P = 0.0003)。肿块大小和可触及性是显著的危险因素(分别为 P < 0.001 和 P < 0.01)。直径≤10 毫米、10 - 20 毫米和>20 毫米的肿块低估率分别为 37%、64%和 91%。 结论:即使是小的超声肿块经微创活检诊断为 DCIS,在最终手术切除后上调至浸润性癌的风险也很高。对于这些患者,需要后续干预来评估淋巴结状态。他们是乳房手术中前哨淋巴结活检的良好候选者,以避免多步骤手术。

相似文献

[1]
Preoperatively diagnosed ductal cancers in situ of the breast presenting as even small masses are of high risk for the invasive cancer foci in postoperative specimen.

World J Surg Oncol. 2015-7-16

[2]
Factors associated with upstaging from ductal carcinoma in situ following core needle biopsy to invasive cancer in subsequent surgical excision.

Breast. 2012-6-30

[3]
Sentinel lymph node biopsy is not necessary in patients diagnosed with ductal carcinoma in situ of the breast by stereotactic vacuum-assisted biopsy.

Breast Cancer. 2016-3

[4]
Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy.

Ann Surg Oncol. 2014-1

[5]
A model to predict upstaging to invasive carcinoma in patients preoperatively diagnosed with ductal carcinoma in situ of the breast.

J Surg Oncol. 2015-10

[6]
Risk predictors of underestimation and the need for sentinel node biopsy in patients diagnosed with ductal carcinoma in situ by preoperative needle biopsy.

J Surg Oncol. 2012-9-24

[7]
Ductal carcinoma in situ diagnosed by breast needle biopsy: Predictors of invasion in the excision specimen.

Breast. 2016-6

[8]
Predictors of residual invasive disease after core needle biopsy diagnosis of ductal carcinoma in situ.

Breast J. 2007

[9]
Is it possible to predict underestimation in ductal carcinoma in situ of the breast? Yes, using a simple score!

Eur J Surg Oncol. 2019-1-14

[10]
Preoperative clinicopathologic factors and breast magnetic resonance imaging features can predict ductal carcinoma in situ with invasive components.

Eur J Radiol. 2016-4

引用本文的文献

[1]
Necessity of sentinel lymph node biopsy in ductal carcinoma in situ patients: a retrospective analysis.

BMC Surg. 2021-3-22

[2]
Biological Aggressiveness of Subclinical No-Mass Ductal Carcinoma In Situ (DCIS) Can Be Reflected by the Expression Profiles of Epithelial-Mesenchymal Transition Triggers.

Int J Mol Sci. 2018-12-7

[3]
Screen-detected ductal carcinoma in situ found on stereotactic vacuum-assisted biopsy of suspicious microcalcifications without mass: radiological-histological correlation.

Radiol Oncol. 2016-4-23

[4]
Breast segmentectomy with rotation mammoplasty as an oncoplastic approach to extensive ductal carcinoma in situ.

World J Surg Oncol. 2016-3-9

本文引用的文献

[1]
Incidence and prediction of invasive disease and nodal metastasis in preoperatively diagnosed ductal carcinoma in situ.

Cancer Sci. 2014-3-26

[2]
Nomogram for predicting invasion in patients with a preoperative diagnosis of ductal carcinoma in situ of the breast.

Br J Surg. 2013-12

[3]
Prediction of underestimated invasiveness in patients with ductal carcinoma in situ of the breast on percutaneous biopsy as rationale for recommending concurrent sentinel lymph node biopsy.

Breast. 2012-12-11

[4]
Risk predictors of underestimation and the need for sentinel node biopsy in patients diagnosed with ductal carcinoma in situ by preoperative needle biopsy.

J Surg Oncol. 2012-9-24

[5]
Predictors of invasive breast cancer and lymph node involvement in ductal carcinoma in situ initially diagnosed by vacuum-assisted breast biopsy: experience of 733 cases.

Breast. 2012-7-12

[6]
Factors associated with upstaging from ductal carcinoma in situ following core needle biopsy to invasive cancer in subsequent surgical excision.

Breast. 2012-6-30

[7]
ACR appropriateness criteria(®) ductal carcinoma in situ.

Breast J. 2011-11-23

[8]
Duration time of vacuum-assisted biopsy for nonpalpable breast masses: comparison between stereotactic and ultrasound-guided procedure.

Tumori. 2011

[9]
Predictors of invasion and axillary lymph node metastasis in patients with a core biopsy diagnosis of ductal carcinoma in situ: an analysis of 255 cases.

Breast J. 2011-3-24

[10]
Surgical outcomes of borderline breast lesions detected by needle biopsy in a breast screening program.

World J Surg Oncol. 2010-9-8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索